- Obinutuzumab in the treatment of non-Hodgkin's B-cell lymphoma - GADOLIN trial2015 | Faculty of Medicine in Hradec Králové
- Time-limited therapy with the combination of venetoclax and obinutuzumab in the first-line treatment of chronic lymphocytic leukemia2023 | Publication without faculty affiliation
- Obinutuzumab a bendamustin2018 | Third Faculty of Medicine
- Therapy of follicular lymphoma in 20192019 | Faculty of Medicine in Hradec Králové
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial2022 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab2014 | Faculty of Medicine in Hradec Králové
- MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial2020 | Faculty of Medicine in Hradec Králové
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové
- Treatment of nonHodgkin lymphoma with monoclonal antibodies in 20192019 | Faculty of Medicine in Hradec Králové
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma2017 | First Faculty of Medicine
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma2017 | Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CAPublication without faculty affiliation
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2023 | Faculty of Medicine in Hradec Králové
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA2020 | First Faculty of Medicine
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- Single-nucleotide Fc gamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma2021 | First Faculty of Medicine
- Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab2019 | First Faculty of Medicine
- Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment2021 | First Faculty of Medicine
- New drugs for the treatment of chronic lymphocytic leukemia2015 | First Faculty of Medicine
- Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial2022 | First Faculty of Medicine
- Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study2023 | Publication without faculty affiliation
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial2016 | First Faculty of Medicine
- Skipping a step or "impatientitis": what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?2021 | Faculty of Medicine in Hradec Králové
- Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy2019 | First Faculty of Medicine
- Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen2022 | Faculty of Medicine in Hradec Králové